Phase 1 and 3 trials demonstrated improved survival rates, with new treatment strategies for EGFR-mutated NSCLC, HER2+ breast cancer, and small-cell lung cancer. AI innovations, such as the ASCO ...
Impact of piflufolastat F18 imaging on disease management for prostate cancer patients: Observations from the PYLARIFY Registry study. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary ...